Drug intelligence / Profile preview

F2B22D + DL001Z

Development stage: Unknown
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

F2B22D + DL001Z is a combination therapy consisting of two monoclonal antibodies: F2B22D, which targets CD47, and DL001Z, which targets PD-L1. Developed by F2 Bio, this combination is designed to enhance the anti-tumor immune response by simultaneously blocking the "don't eat me" signal (CD47) and the PD-1/PD-L1 checkpoint. By inhibiting CD47, F2B22D promotes the phagocytosis of cancer cells by macrophages, while DL001Z prevents T-cell exhaustion by blocking the interaction between PD-L1 on tumor cells and PD-1 on T-cells. The combination is currently being evaluated in clinical trials for the treatment of advanced solid tumors.

Other names: F2B22D + DL001Z

Targets

CD47 (Cluster of Differentiation 47)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on F2B22D + DL001Z.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F2B22D + DL001Z.

Explore the full profile